8682 Federal Register / Vol. 89, No. 27 / Thursday, February 8, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP24–031, Epidemiologic Cohort Study 

of Interstitial Cystitis. 

Date: April 10, 2024. 

Time: 10 a.m.–6 p.m., EDT. 

Place: Teleconference/Web 

Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Catherine Barrett, Ph.D., Scientific 

Review Officer, National Center for 

Chronic Disease Prevention and Health 

Promotion, Centers for Disease Control 

and Prevention, 4770 Buford Highway, 

Mailstop S106–3, Atlanta, Georgia 

30341–3717. Telephone: (404) 718– 

7664; Email: CBarrett@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–02514 Filed 2–7–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket Nos. FDA–2023–N–2894; FDA– 

2023–N–1929; FDA–2017–N–5569; FDA– 

2023–N–2564; FDA–2023–N–2851; FDA– 

2023–N–1554] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approvals 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is publishing a 

list of information collections that have 

been approved by the Office of 

Management and Budget (OMB) under 

the Paperwork Reduction Act of 1995. 

FOR FURTHER INFORMATION CONTACT: 

Amber Sanford, Office of Operations, 

Food and Drug Administration, Three 

White Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–8867, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

following is a list of FDA information 

collections recently approved by OMB 

under section 3507 of the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3507). 

The OMB control number and 

expiration date of OMB approval for 

each information collection are shown 

in table 1. Copies of the supporting 

statements for the information 

collections are available on the internet 

at https://www.reginfo.gov/public/do/ 

PRAMain. An Agency may not conduct 

or sponsor, and a person is not required 

to respond to, a collection of 

information unless it displays a 

currently valid OMB control number. 

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB 

Title of collection OMB control No. Date approval 

expires 

Good Laboratory Practice (GLP) Regulations for Nonclinical Laboratory Studies ......................................... 0910–0119 1/31/2027 

Orphan Drugs .................................................................................................................................................. 0910–0167 1/31/2027 

Medical Devices; Device Tracking .................................................................................................................. 0910–0442 1/31/2027 

Channels of Trade Policy for Commodities with Residues of Pesticide Chemicals for Which Tolerances 

Have Been Revoked, Suspended, or Modified by the EPA ........................................................................ 0910–0562 1/31/2027 

Time and Extent Applications for Nonprescription Drug Products .................................................................. 0910–0688 1/31/2027 

Qualitative Feedback on Food and Drug Administration Service Delivery ..................................................... 0910–0697 1/31/2027 

Dated: February 5, 2024. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2024–02579 Filed 2–7–24; 8:45 am] 

BILLING CODE 4164–01–P 


lotter on DSK11XQN23PROD with NOTICES1